Updates from the ACCORD platform
First arm of ACCORD clinical trial platform completes patient recruitment
ACCORD – a Phase 2, clinical trial platform designed to rapidly test candidate drugs for the treatment of COVID-19 – has completed patient recruitment for the first of its arms.
The ongoing study is delivered in collaboration with the Medicines Evaluation Unit in Manchester and NHS hospital sites across the UK, supported by the NIHR. ACCORD is led by Professor Tom Wilkinson at the NIHR Southampton Biomedical Research Centre.
ACCORD’s work evaluating new candidate drugs for large scale trials is vital, with only limited treatment options for those who are hospitalised with COVID-19. Despite vaccine programmes helping to reduce COVID-19 cases and incidence of severe COVID-19, new treatments will remain critical to improving outcomes for hospitalised patients and reducing pressure on intensive care units.
Analysis of the full dataset from ACCORD is expected to be completed in the next few months following completion of patient recruitment in the additional two arms.
Statement from the UK Early Phase platforms (TACTIC, ACCORD, CATALYST, DEFINE)
Profs David Jayne (TACTIC), Pam Kearns (CATALYST), Kev Dhaliwal (DEFINE), Tom Wilkinson (ACCORD), Maya Buch (MSK-TRC) and Ling-Pei Ho (Respiratory-TRC). 8 June 2020
The four national early phase platform trials (TACTIC, CATALYST, DEFINE and ACCORD) have today formally agreed to work as an alliance to accelerate patient recruitment, data analysis and delivery of therapeutic drugs for COVID-19 patients. They will be supported by the MSK and Respiratory TRC, the NIHR Clinical Research Network and the UK network of CRFs.
We will jointly review drugs and sites in a transparent manner, communicate our collaborative and common purpose to all sites that we approach, share our data at appropriate milestones, and support each other's efforts. The alliance will work closely with the NIHR BRCs and offer UK-wide early phase trials capability for the current COVID-19 and preparedness for future waves.
Latest news coverage